Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Marts 2025

Genmab — Marts 2025

Planlagt Fastgjort Låst Flyttet Genmab
961 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • T Offline
    T Offline
    transalp
    wrote on sidst redigeret af
    #895

    Go morgen.. 🙂

    1 Reply Last reply
    0
    • J Offline
      J Offline
      JKY_VH
      wrote on sidst redigeret af
      #896

      Aktietilbagekøbsprogrammet på op til 4 mia. kr. løber frem til den 10 juli 2025. Der skal altså handles en del aktier de næste 3,5 måneder.

      1 Reply Last reply
      0
      • J Offline
        J Offline
        JKY_VH
        wrote on sidst redigeret af
        #897

        Mon de regner med gode nyheder indenfor den tidshorisont, således at aktien er selvkørende herefter?

        1 Reply Last reply
        0
        • DarvinD Offline
          DarvinD Offline
          Darvin
          wrote on sidst redigeret af
          #898

          Thanks E L Great to see the pace and quality Genmab is showing with their pipeline. They are managing their resources extremely well.

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #899

            And their resources have exploded over the last few years with the immens growth in staff. Someone mentioned a concern the other day about the own R&D capacity of Genmab, with all the focus on Rina-S and the disappointment of Hexabody-CD38.

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #900

              I think we should see much of that in the light of the continued questions by investors about a potential revenue gap in the early 2030s, so Genmab has tried to steer investors attention that way.

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #901

                But that doesn't mean that they stopped their R&D, on the contrary; we should expect to see a vastly larger stream of R&D news than in the years before i would think.

                1 Reply Last reply
                0
                • DarvinD Offline
                  DarvinD Offline
                  Darvin
                  wrote on sidst redigeret af
                  #902

                  Totally agree E L There is a lot going on. Unfortunately, the questions investors ask and the topics discussed, for example, here on PI, affect the perception and formation of opinions about the stock. There is a lot more going on than CD38 and a baseless harassment accusation.

                  1 Reply Last reply
                  0
                  • DarvinD Offline
                    DarvinD Offline
                    Darvin
                    wrote on sidst redigeret af
                    #903

                    Right now I'm convinced that those who are patient will be rewarded 😉

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #904

                      I think you will be right, but i also think that many long term investors that were patient for a long time have thrown in the towel. And if you are right they will not benefit. Markets can be brutal. But only time will tell...

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #905

                        Genmab: Laser-skarpt fokus trods HexaBody tilbageslag

                        David Mygind
                        tirsdag 25. marts 2025 https://ugebrev.dk/life-science/genmab-laser-skarpt-fokus-trods-hexabody-tilbageslag/

                        1 Reply Last reply
                        0
                        • nohopeN Offline
                          nohopeN Offline
                          nohope
                          wrote on sidst redigeret af
                          #906

                          I wouldn´t trust any word from Mygind, he has been perma-bull for the last 15 years and GEN should have been in +5000 according to his writings - long time ago.

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            lahn1
                            wrote on sidst redigeret af
                            #907

                            Er det noget økonomisk forhold mellem Mygind og Genmab ? 🙂

                            1 Reply Last reply
                            0
                            • J Offline
                              J Offline
                              JKY_VH
                              wrote on sidst redigeret af
                              #908

                              det er der jo, hvis man er aktionær, men det er nok ikke det du tænker på lahn1:-)

                              1 Reply Last reply
                              0
                              • J Offline
                                J Offline
                                JKY_VH
                                wrote on sidst redigeret af
                                #909

                                Investor lurer på dansk aktie: “Kursen er banket godt og grundigt i bund”. https://borsen.dk/nyheder/podcast/investor-lurer-pa-dansk-aktie-kursen-er-banket-godt-og-grundigt-i-bund?b_source=borsen&b_medium=row_-1&b_campaign=latest_news_2

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  Plimsoller
                                  wrote on sidst redigeret af
                                  #910

                                  Vi kan godt blive enige om at den er banket godt og grundigt i bund, men de skal altså gøre mere end at lure.

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    Plimsoller
                                    wrote on sidst redigeret af
                                    #911

                                    Er der iøvrigt nogen der ved om sagsanlægget fra AbbVie er kommet længere end at det stadigvæk blot kan afvises af en dommer hvis vi ellers kunne være så heldige?

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #912

                                      RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-outperforms-osimertinib-with-a-significant-and-unprecedented-overall-survival-benefit-in-patients-with-egfr-mutated-non-small-cell-lung-cancer

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #913

                                        J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca’s Tagrisso https://www.fiercepharma.com/pharma/jj-combo-signals-new-era-egfr-lung-cancer-survival-win-against-astrazenecas-tagrisso

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #914

                                          Link Preview Image

                                          favicon

                                          X (formerly Twitter) (x.com)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper